These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23008298)

  • 21. [Severe, bilateral vision loss in malignant melanoma of the skin. Anterior ischemic optic neuropathy with irreversible vision and visual field loss in adjuvant interferon alfa-2b therapy].
    Gabler B; Kroher G; Bogenrieder T; Spiegel D; Preuner J; Lohmann CP
    Ophthalmologe; 2001 Jul; 98(7):672-3. PubMed ID: 11490747
    [No Abstract]   [Full Text] [Related]  

  • 22. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 23. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
    Busse A; Rapion J; Fusi A; Suciu S; Nonnenmacher A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Cancer Immunol Immunother; 2013 Jul; 62(7):1223-33. PubMed ID: 23624802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
    Agarwala SS; Gray RJ; Wong MK
    J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of adjuvant therapy in cutaneous melanoma.
    Sondak VK
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):421-6. PubMed ID: 12113108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
    Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complete remission of Crohn's disease after high-dose alpha-interferon treatment for malignant melanoma].
    Ferre Aracil C; Rodríguez de Santiago E; García García de Paredes A; Aguilera Castro L; Soria Rivas A; López SanRomán A
    Gastroenterol Hepatol; 2016; 39(6):397-400. PubMed ID: 26096290
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
    Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
    Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant melanoma: non-metastatic.
    Crosby D; Crosby T; Mason M
    Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
    [No Abstract]   [Full Text] [Related]  

  • 31. Thyrotoxicosis with pegylated interferon alfa-2b.
    Lowndes SA; Asher R; Middleton MR
    Arch Dermatol; 2010 Nov; 146(11):1273-5. PubMed ID: 21079065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy for melanoma: a surgical perspective.
    Sondak VK; Gonzalez RJ; Kudchadkar R
    Surg Oncol Clin N Am; 2011 Jan; 20(1):105-14. PubMed ID: 21111961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant interferon in high-risk melanoma: end of the era?
    Janku F; Kurzrock R
    J Clin Oncol; 2010 Jan; 28(2):e15-6; author reply e17-8. PubMed ID: 19949007
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of cutaneous melanoma.
    Tsao H; Atkins MB; Sober AJ
    N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
    [No Abstract]   [Full Text] [Related]  

  • 35. Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186).
    Sulkes A; Schachter J
    Ann Oncol; 2002 Apr; 13(4):637. PubMed ID: 12056717
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
    Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Malignant melanoma. Less recurrence with interferon].
    MMW Fortschr Med; 2001 Feb; 143(5):55. PubMed ID: 11236804
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 40. Approaches to regional nodes in patients with melanoma.
    Deperalta DK; Hoang MP; Tanabe KK
    J Clin Oncol; 2014 Mar; 32(9):881-5. PubMed ID: 24516017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.